



# **Accepted Article**

**Title:** Novel aminomethyl derivatives of 4-methyl-2-prenylphenol: synthesis and antioxidant properties

Authors: Evgeny Buravlev, Irina V. Fedorova, Oksana G. Shevchenko, and Aleksandr V. Kutchin

This manuscript has been accepted after peer review and appears as an Accepted Article online prior to editing, proofing, and formal publication of the final Version of Record (VoR). This work is currently citable by using the Digital Object Identifier (DOI) given below. The VoR will be published online in Early View as soon as possible and may be different to this Accepted Article as a result of editing. Readers should obtain the VoR from the journal website shown below when it is published to ensure accuracy of information. The authors are responsible for the content of this Accepted Article.

To be cited as: Chem. Biodiversity 10.1002/cbdv.201800637

Link to VoR: http://dx.doi.org/10.1002/cbdv.201800637

www.cb.wiley.com



# Novel aminomethyl derivatives of 4-methyl-2-prenylphenol:

# synthesis and antioxidant properties

Evgeny V. Buravlev, \*,ª Irina V. Fedorova, \* Oksana G. Shevchenko, b and Aleksandr V. Kutchin \*

<sup>a</sup>Institute of Chemistry, Komi Scientific Centre, Ural Branch of the Russian Academy of Sciences, 48, Pervomayskaya St., 167000, Syktyvkar, Komi Republic, Russian Federation, e-mail: eugeneburavlev@gmail.com <sup>b</sup>Institute of Biology, Komi Scientific Centre, Ural Branch of the Russian Academy of Sciences, 28, Kommunisticheskaya St., 167982, Syktyvkar, Komi Republic, Russian Federation

4-Methyl-2-prenylphenol (1) was synthesized from *para*-cresol and prenol, natural alcohol under the conditions of heterogeneous catalysis. A series of nine new aminomethyl derivatives with secondary and tertiary amino groups were obtained on the basis of compound **1**. A comparative evaluation of their antioxidant properties was carried out using *in vitro* models. It was established that Mannich base with *n*-octylaminomethyl group has radical scavenging activity, high Fe<sup>2+</sup>-chelation ability as well as the ability to inhibit oxidative hemolysis of red blood cells.

Keywords: alkylation o Mannich bases o antioxidants o red blood cells o oxidative hemolysis

# Introduction

Prenylphenol moiety is the base for skeleton or is a part of structural backbone in many natural metabolites<sup>[1]</sup> that have a wide range of biological properties.<sup>[1-6]</sup> The presence of *C*-prenyl groups in the phenol molecule increases a compound's lipophilicity and its affinity to biological membranes.<sup>[7]</sup> The presence of activated reaction centers of the aromatic system in the molecules of prenylphenol derivatives opens up potential for their further functionalization using the reaction of electrophilic substitution, e.g. for aminomethylation.<sup>[8]</sup> The introduction of an aminomethyl group is often used in drug design and medicinal chemistry.<sup>[9]</sup> This structural fragment can be formed using the Mannich reaction,<sup>[8]</sup> as well as using other synthetic approaches: via reduction of Schiff bases,<sup>[10]</sup> by the interaction of bromomethyl derivatives with amines,<sup>[11]</sup> through Rh-catalyzed C– H functionalization,<sup>[12]</sup> etc. There are various examples of the influence of aminomethyl substituents on the biological properties of prenylphenol compounds (Fig. 1). Thus, Mannich bases obtained from the antibiotic novobiocin were characterized by reduced antibacterial activity,<sup>[13]</sup> while aminomethyl derivatives of the flavonoid icaritin isolated from *Epimedium Genius* had a greater cytotoxicity against human cancer cells in a several cases.<sup>[14]</sup> For Mannich bases derived from prenylated xanthones α- and γ-mangostins isolated from *Garcinia mangostana* L, an increase in antioxidant (AO) and membrane-protective (MP) properties and a significant decrease in hemolytic activity was shown in most cases.<sup>[15]</sup>



Figure 1. Examples of naturally occurring compounds with prenylphenol moieties used in the Mannich reaction. Arrows indicate positions for aminomethylation.

anuscri

#### **Chem. Biodiversity**

The aim of this work was to synthesize new aminomethyl derivatives containing an *ortho*-prenylphenol moiety, and to assess the compounds obtained as inhibitors of oxidative processes *in vitro*.

# **Results and Discussion**

As the initial backbone structure we used 4-methyl-2-prenylphenol (1), which was obtained by alkylation of *para*-cresol with prenol (3-methylbut-2-en-1-ol) under the conditions of heterogeneous catalysis using montmorillonite KSF clay (Scheme 1, path *a*).<sup>1</sup> Aminomethyl derivatives of the compound **1** containing a tertiary amino group **2** – **7** were synthesized by the Mannich reaction using various conditions (Scheme 1, paths *b* – *d*): for the synthesis of amine **2**, aqueous solutions of formaldehyde and dimethylamine were used, amines **3** – **6** were obtained using HCHO and the corresponding secondary amines (di-*n*-butylamine, morpholine, piperidine, and azepane), and 1,4-disubstituted piperazine **7** was synthesized using aminomethyl reagent in the presence of CaCl<sub>2</sub> under solvent-free conditions.<sup>[17]</sup> Aldehyde **8** was obtained by the Casiraghi reaction<sup>[18]</sup> from cresol **1** (Scheme 1, path *e*), and imines **9** – **11** were synthesized (Scheme 1, path *f*). Mannich bases with cyclopropylamine **12**, *n*-butylamine **13**, and *n*-octylamine **14** groups were obtained as a result of reduction reaction of the corresponding Schiff bases **9** – **11** (Scheme 1, path *g*).



Scheme 1. Synthesis of compounds 1 – 14. Reagents and conditions: *a*. prenol, montmorillonite KSF, CH<sub>2</sub>Cl<sub>2</sub>, 40 °C, 2 h; *b*. HCHO (aq.), Me<sub>2</sub>NH (aq.), MeOH, r.t., 24 h; *c*. HCHO, di-*n*-butylamine, morpholine, piperidine or azepane, benzene, reflux, 6 – 12 h; *d*. HCHO, piperazine, CaCl<sub>2</sub>, 110 °C, 35 min; *e*. HCHO, SnCl<sub>4</sub>, tri-*n*-butylamine, toluene, reflux, 10 h;<sup>(18)</sup> *f*. cyclopropylamine, *n*-butylamine or *n*-octylamine, molecular sieves (4 Å), benzene, reflux, 3.5 h; *g*. NaBH<sub>4</sub>, EtOH, reflux, 30 min.

The results of <sup>1</sup>H-, <sup>13</sup>C-NMR, IR-spectroscopy and elemental analysis of novel products **2** – **14** were consistent with the expected structures. The spectral characteristics of compound **1** are consistent with those previously described.<sup>[19]</sup> In the <sup>1</sup>H- and <sup>13</sup>C-NMR spectra of the obtained compounds, signals of additional substituents in the *ortho*-position relative to the phenolic hydroxyl group were observed in addition to the signals of the prenylcresol skeleton. Schiff bases **9** – **11** had the *E*-configuration of substituents relative to the C=N bond: the NOESY experiment for these compounds showed interactions of the protons of N=CH group ( $\delta_{H} 8.3 - 8.4$  ppm) with the protons of C(3)H ( $\delta_{H} 6.9$  ppm) and the protons of NCH fragments ( $\delta_{H} 2.9 - 3.0$  ppm for imine **9**, see Fig. 2) or NCH<sub>2</sub> fragments ( $\delta_{H} 3.6$  ppm for imines **10** and **11**<sup>2</sup>), evidencing their spatial convergence.



Figure 2. NOE-interactions of imine 9 that show E-configuration.

<sup>&</sup>lt;sup>1</sup> A separate paper will be devoted to this alkylation reaction.

<sup>&</sup>lt;sup>2</sup> See Fig. S9 (Supporting information).

Design and synthesis of new compounds with potential use in pharmacology should be accompanied by a rigorous study of the mechanics of their biological activity. In particular, for the phenols it is important to study their radical scavenging activity (RSA).<sup>[20]</sup> A study of toxicity of the obtained compounds using various *in vitro* tests is also an important part.<sup>[21]</sup>

For aminomethyl derivatives **2** – **7**, **12** – **14**, RSA (Fig. 3), AO activity (AOA) were assessed on a substrate obtained from the brain of laboratory mice; Fe<sup>2+</sup>-chelation ability (Table 1), as well as hemolytic activity (cytotoxicity), AO and MP properties with the use of red blood cells (RBCs) were also assessed (Table 2) in the work. The above approaches have been previously successfully used by us to assess the AO properties of prenylated xanthones,<sup>[15][16]</sup> aminomethhylated terpenylphenols,<sup>[11]</sup> sulfur-containing terpenoids,<sup>[22]</sup> and non-steroidal anti-inflammatory drugs.<sup>[23]</sup> 4-Methyl-2-prenylphenol (**1**) and the known antioxidant 2,6-di-*tert*-buthyl-4-methylphenol (BHT) were used as reference compounds.

Study in non-cellular model systems (Fig. 3, Table 1) showed that compounds **1**, **2**, **13**, and **14** at a concentration of 100  $\mu$ M had a moderate ability to neutralize the stable radical 2,2-diphenyl-1-picrylhydrazyl (DPPH), which was comparable to BHT, while derivatives **3**, **6**, and **12** were significantly superior in the RSA to the original cresol **1** and BHT (Fig. 3). The increase in the Fe<sup>2+</sup>-chelation ability of derivatives **2** – **7**, **12** – **14** compared with BHT and compound **1**, can be explained by the presence of aminomethyl groups, which cause an increase in the coordination properties in the structures of these derivatives. High Fe<sup>2+</sup>-chelation ability in phenols containing an aminomethyl fragment in the *ortho*-position is also known from the literature.<sup>[8]</sup> All the synthesized compounds, with the exception of tertiary amines **3** and **7**, inhibited Fe<sup>2+</sup>/ascorbate-initiated accumulation of secondary lipid peroxidation (LPO) products to a level substantially below the spontaneous one and were not inferior in the activity to BHT (Table 1).



Figure 3. Comparative evaluation of RSA (test with DPPH) of the derivatives at a concentration of 100 μM.

Table 1. Comparative evaluation of Fe<sup>2+</sup>-chelation ability (test with FerroZine<sup>™</sup> Iron Reagent) and AOA (test on the substrate from brain)<sup>a</sup> of the derivatives at a concentration of 100 µM

| Compound | Fe <sup>2+</sup> -chelation ability (%) | TBA-RS (nmol/mL) |
|----------|---|------------------|
| BHT      | 6.1 ± 1.0                               | $5.4 \pm 0.2$    |
| 1        | 8.6 ± 1.9                               | $5.0\pm0.2$      |
| 2        | 47.3 ± 2.1                              | $5.1\pm0.2$      |
| 3        | 43.8 ± 1.0                              | $10.2 \pm 0.1$   |
| 4        | 37.1 ± 1.5                              | $6.7\pm0.2$      |
| 5        | 42.7 ± 1.7                              | $5.3 \pm 0.1$    |
| 6        | 48.3 ± 1.0                              | $5.5\pm0.1$      |
| 7        | $31.8\pm0.5$                            | $20.0\pm0.3$     |
| 12       | 44.1 ± 1.8                              | $5.0\pm0.1$      |
| 13       | $71.5\pm0.9$                            | $4.9\pm0.1$      |
| 14       | $73.2\pm0.9$                            | $4.8\pm0.1$      |

<sup>a</sup> The ability to inhibit the accumulation of secondary LPO products reacting with 2-thiobarbituric acid (thiobarbituric acid reactive substances, TBA-RS) in an organic substrate 1 h after initiating LPO with Fe<sup>2+</sup>/ascorbate was assessed. TBA-RS concentration in the control (without the compounds) and intact (without oxidation initiated) samples was 40.5  $\pm$  0.3 and 17.2  $\pm$  0.1 nmol/mL, respectively

Assessment of hemolytic activity showed that the studied compounds at a concentration of 10  $\mu$ M did not have significant cytotoxicity against RBCs (cell survival during 5 h of incubation was >90%). Despite the high RSA of most of the obtained Mannich bases, only secondary amine **14** at a concentration of 1  $\mu$ M effectively protected living cells under the conditions of acute H<sub>2</sub>O<sub>2</sub>-induced oxidative stress. Compound **14** was not only significantly superior to BHT in its ability to inhibit hemolysis of RBCs, but also reduced the content of secondary LPO products in them (Table 2).

In addition, there was a decrease in the methemoglobin/oxyhemoglobin and ferrylhemoglobin/oxyhemoglobin ratios by 1.9 and 1.6 times, respectively (data not shown in the Table 2). It should be noted, that differences in activity between compounds **13** and **14** containing *n*-butylaminomethyl and *n*-octylaminomethyl groups were only found in these studies on living cells. Thus, the high AOA of the Mannich base with *n*-octylaminomethyl fragment **14** in the cellular model system may be due to the combination of several functional groups in the molecule – the phenol hydroxyl group providing RSA, the secondary amino group, which causes high chelation ability, and, finally, two lipophilic (prenyl and *n*-octylaminomethyl) fragments, which appear to contribute to the optimal interaction of compound **14** with the biomembrane.

| Compound | Membrane-protective activity (hemolysis, %) |                |                | TBA-RS (nmol/mL) |
|----------|---|----------------|----------------|------------------|
|          | 1 h   | 3 h            | 5 h            |                  |
| Control  | 18.0 ± 1.6                                  | 44.9 ± 1.6     | $55.0 \pm 1.4$ | 1.67 ± 0.06      |
| BHT      | $2.9\pm0.3$                                 | $13.9\pm0.8$   | $20.9\pm0.8$   | $0.94\pm0.09$    |
| 1        | 14.6 ± 1.6                                  | 38.0 ± 1.9     | 49.9 ± 1.8     | 1.21 ± 0.09      |
| 2        | $9.4 \pm 0.9$                               | $32.2\pm0.8$   | $45.7\pm0.6$   | $0.98\pm0.06$    |
| 3        | 24.0 ± 1.6                                  | $39.2 \pm 0.4$ | $52.0\pm0.6$   | $1.02\pm0.02$    |
| 4        | $13.4 \pm 0.3$                              | 38.6 ± 1.0     | $48.9\pm0.9$   | 1.06 ± 0.01      |
| 5        | 10.9 ± 0.8                                  | 35.9 ± 0.5     | 49.0 ± 1.1     | $1.11 \pm 0.03$  |
| 6        | $12.2 \pm 0.2$                              | 49.3 ± 1.0     | $65.5\pm0.3$   | $1.16 \pm 0.06$  |
| 7        | 13.0 ± 1.5                                  | 31.1 ± 2.5     | 42.7 ± 3.5     | 1.29 ± 0.13      |
| 12       | 28.0 ± 2.2                                  | 60.0 ± 1.8     | $66.0 \pm 1.5$ | $1.79 \pm 0.04$  |
| 13       | 11.0 ± 0.6                                  | $24.9\pm0.4$   | $39.5 \pm 0.4$ | 1.17 ± 0.03      |
| 14       | $1.4 \pm 0.4$                               | 3.3 ± 0.1      | $10.1 \pm 0.4$ | $1.10 \pm 0.03$  |

Table 2. Comparative evaluation of MPA and AOA of the derivatives at a concentration of 1  $\mu$ M on the model of RBCs oxidative hemolysis

# Conclusions

Thus, in this work, 4-methyl-2-prenylphenol (1) was obtained and a series of nine novel Mannich bases containing tertiary and secondary amino groups was synthesized using simple transformations. For the synthesized derivatives 2 – 7, 12 – 14 radical scavenging activity and antioxidant activity were assessed on an organic substrate containing animal lipids, as well as Fe<sup>2+</sup>-chelation ability, antioxidant, and membrane-protective properties using RBCs. It was shown that with respect to a set of indicators characterizing the studied compounds as inhibitors of oxidative processes, the most optimal bio-antioxidant was Mannich base 14 with *n*-octylaminomethyl fragment.

## **Experimental Section**

#### General

The spectral data were obtained using the equipment of the Centre of Collective Usage 'Chemistry', Institute of Chemistry, Komi Scientific Centre, Ural Branch of the RAS. The IR spectra were recorded on a 'Shimadzu IR Prestige 21' FT-IR spectrometer. The <sup>1</sup>H-, <sup>13</sup>C-NMR spectra were recorded on a 'Bruker Avance II 300' instrument. The chemical shifts were referenced to the residual signals of CHCl<sub>3</sub> ( $\delta_H$  = 7.26 ppm,  $\delta_C$  = 77.00 ± 0.42 ppm). The signals of carbon atoms were assigned using NMR <sup>13</sup>C spectra in *J*-modulation mode; some assignments were made using NOESY, HSQC, and HMBC experiments. The melting points were measured on a 'Sanyo Gallenkamp MPD 350' instrument and were not corrected. The 'Elementar vario MICRO cube' instrument was employed for elemental analysis.

The course of reactions was monitored by thin-layer chromatography (TLC) on a 'Sorbfil' plates. To detect the components, the plates were exposed to KMnO<sub>4</sub> solution (15.0 g of KMnO<sub>4</sub>, 300 mL of H<sub>2</sub>O, 0.5 mL of concentrated H<sub>2</sub>SO<sub>4</sub>). Silica gel 60 ('Alfa Aesar', 0.06 – 0.2 mm) was used for column chromatography.

Commercially available *para*-cresol, prenol, montmorillonite KSF, piperidine, azepane, anhydrous piperazine, SnCl₄, tri-*n*-butylamine, cyclopropylamine, *n*-octylamine, BHT, DPPH ('Alfa Aesar'), dimethylamine (40% aq. solution), FerroZine<sup>™</sup> Iron Reagent ('Sigma-Aldrich'), di-*n*-butylamine, morpholine, *n*-butylamine ('Acros Organics'), formaldehyde (37% aq. solution), and paraform (reagent-grade quality) were used without additional purification. Petroleum ether (PE) with b.p. 65 – 70 °C was used freshly distilled. Molecular sieves (4 Å) were used after heating for 3 h at 140 °C.

The *in vitro* assays were done using the equipment of the Centre of Collective Usage 'Molecular Biology', Institute of Biology, Komi Scientific Centre, Ural Branch of the RAS. The mice from the scientific collection of experimental animals of Institute of Biology, Komi Scientific Centre, Ural Branch of the RAS (http://www.ckp-rf.ru/usu/471933/) were used in the work. The optical density was measured on a spectrophotometer 'Thermo Spectronic Genesys 20'; the absorption spectra of hemolysates were analyzed using 'Fluorat-02-Panorama' spectrofluorimeter. Incubation of brain homogenates and mice erythrocytes were carried out in thermostated 'Biosan ES-20' shaker. Compounds **1** – **7**, **12** – **14**, and BHT were dissolved in an acetone for the *in vitro* experiments.

#### Synthesis of compound 1

Prenol (3.76 mL, 37.0 mmol) and montmorillonite KSF (2.0 g) were added to the solution of *para*-cresol (2.0 g, 18.5 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (20 mL). The reaction mixture was heated for 2 h with stirring at 40 °C. At the end of the reaction, the clay was separated by filtration, washed with CH<sub>2</sub>Cl<sub>2</sub>, the solvent was removed under reduced pressure, the product was isolated by column chromatography (PE/Et<sub>2</sub>O 5:1  $\rightarrow$  3:1).

**4-Methyl-2-(3-methylbut-2-en-yl)phenol (1).** Light yellow oil. Yield 2.0 g (61%).  $R_f = 0.52$  (PE/Et<sub>2</sub>O 5:1). The spectral characteristics of the compound are consistent with those presented in the work.<sup>[19]</sup>

#### Synthesis of compound 2

Formaldehyde (37% aq. solution, 0.11 mL, 1.5 mmol) and dimethylamine (40% aq. solution, 0.19 mL, 1.5 mmol) were added to the solution of cresol **1** (0.22 g, 1.25 mmol) in MeOH (1 mL). The reaction mixture was stirred for 24 h at r.t. At the end of the reaction, the solvent was removed under reduced pressure, the product was isolated by column chromatography (PE/Et<sub>2</sub>O 20:1  $\rightarrow$  3:1).

**2-((Dimethylamino)methyl)-4-methyl-6-(3-methylbut-2-en-1-yl)phenol (2).** Colorless oil. Yield 0.218 g (75%). *R*<sub>f</sub> = 0.31 (PE/Et<sub>2</sub>O 5:1). Anal. calc. for C<sub>15</sub>H<sub>23</sub>NO (233.36): C 77.21, H 9.94, N 6.00; found: C 76.98, H 10.12, N 6.06. IR (thin layer): 2959, 2928, 2866, 2818, 2735, 1476, (CH<sub>3</sub>, CH<sub>2</sub>); 1611 (C–H); 1248, 1150 (C–O); 858, 785 (=C–H). <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): 1.74 (*s*, 3 H, C(11)H<sub>3</sub>); 1.75 (*s*, 3 H, C(10)H<sub>3</sub>); 2.23 (*s*, 3 H, ArCH<sub>3</sub>); 2.31 (*s*, 6 H, N(CH<sub>3</sub>)<sub>2</sub>); 3.31 (*d*, 2 H, *J* = 7.2, C(7)H<sub>2</sub>); 3.58 (*s*, 2 H, ArCH<sub>2</sub>N); 5.35 (*br. t*, 1 H, *J* = 7.5, C(8)H); 6.63 (*s*, 1 H, C(5)H); 6.85 (*s*, 1 H, C(3)H); 10.71 (*br. s*, 1 H, OH). <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>): 17.77 (C(11)); 20.51 (ArCH<sub>3</sub>); 25.79 (C(10)); 28.04 (C(7)); 44.42 (N(CH<sub>3</sub>)<sub>2</sub>); 62.94 (ArCH<sub>2</sub>N); 121.16 (C(6)); 123.00 (C(8)); 126.50 (C(5)); 127.47, 128.05 (C(2), C(4)); 129.06 (C(3)); 131.97 (C(9)); 153.31 (C(1)).

#### Synthesis of compounds 3 – 6

Paraform (0.075 g, 2.5 mmol) and amine (2.5 mmol) were added to the solution of cresol **1** (0.22 g, 1.25 mmoL) in anhydrous benzene (5 mL). The reaction mixture was refluxed for 6 h (piperidine, azepane) or 12 h (di-*n*-butylamine, morpholine). At the end of the reaction, the solvent was removed under reduced pressure, the product was isolated by column chromatography (PE/Et<sub>2</sub>O, with an increase in the fraction of the latter).

**2-((Di-***n***-buthylamino)methyl)-4-methyl-6-(3-methylbut-2-en-1-yl)phenol (3).** Colorless oil. Yield 0.358 g (90%). *R*<sub>f</sub> = 0.86 (PE/Et<sub>2</sub>O 5:1). Anal. calc. for C<sub>21</sub>H<sub>35</sub>NO (317.52): C 79.44, H 11.11, N 5.04; found: C 79.57, H 11.01, N 5.01. IR (thin layer): 2978, 2953, 2914, 2858, 2826, 2781, 1476 (CH<sub>3</sub>, CH<sub>2</sub>); 1611 (C–H); 1250, 1146 (C–O); 864, 783 (=C–H). <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): 0.90 (*t*, 3 H, *J* = 7.3, N(CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>)<sub>2</sub>); 1.21 – 1.39 (*m*, 4 H, N(CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>)<sub>2</sub>); 1.72 (*s*, 3 H, C(11)H<sub>3</sub>); 1.74 (*s*, 3 H, C(10)H<sub>3</sub>); 2.22 (*s*, 3 H, ArCH<sub>3</sub>); 2.42 – 2.53 (*m*, 4 H, N(CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>)<sub>2</sub>); 3.34 (*d*, 2 H, *J* = 7.2, C(7)H<sub>2</sub>); 3.69 (*s*, 2 H, ArCH<sub>2</sub>N); 5.36 (*br*. *t*, 1 H, *J* = 6.8, C(8)H); 6.62 (*s*, 1 H, C(5)H); 6.83 (*s*, 1 H, C(3)H); 11.07 (*br*. *s*, 1 H, OH). <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>): 13.96 (N(CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>)<sub>2</sub>); 17.77 (C(11)); 20.57 (N(CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>)<sub>2</sub>); 20.57 (ArCH<sub>3</sub>); 25.80 (C(10)); 27.97 (C(7)); 28.46 (N(CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>)<sub>2</sub>); 53.07 (N(CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>)<sub>2</sub>); 53.01 (C(8)); 126.60 (C(5)); 127.36, 128.04 (C(2), C(4)); 128.78 (C(3)); 131.93 (C(9)); 153.35 (C(1)).

**4-Methyl-2-(3-methylbut-2-en-1-yl)-6-(morpholinomethyl)phenol (4).** Colorless oil. Yield 0.308 g (90%). *R*<sub>f</sub> = 0.28 (PE/Et<sub>2</sub>O 5:1). Anal. calc. for C<sub>17</sub>H<sub>25</sub>NO<sub>2</sub> (275.39): C 74.14, H 9.15, N 5.09; found: C 74.31, H 8.99, N 5.06. C<sub>17</sub>H<sub>25</sub>NO<sub>2</sub>. IR (thin layer): 3455 (OH); 2963, 2914, 2853, 2822, 1478, 1452 (CH<sub>3</sub>, CH<sub>2</sub>); 1612 (C–H); 1246, 1119 (C–O); 864, 783 (=C–H). <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): 1.73 (*s*, 3 H, C(11)H<sub>3</sub>); 1.75 (*s*, 3 H, C(10)H<sub>3</sub>); 2.22 (*s*, 3 H, ArCH<sub>3</sub>); 2.40 – 2.72 (*m*, 4 H, N(CH<sub>2</sub>CH<sub>2</sub>)<sub>2</sub>O); 3.30 (*d*, 2 H, *J* = 7.1, C(7)H<sub>2</sub>); 3.60 – 3.90 (*m*, 4 H, N(CH<sub>2</sub>CH<sub>2</sub>)<sub>2</sub>O); 3.65 (*s*, 2 H, ArCH<sub>2</sub>N); 5.33 (*br. t*, 1 H, *J* = 6.9, C(8)H); 6.65 (*s*, 1 H, C(5)H); 6.86 (*s*, 1 H, C(3)H); 10.54 (*br. s*, 1 H, OH). <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>): 17.78 (C(11)); 20.48 (ArCH<sub>3</sub>); 25.78 (C(10)); 28.02 (C(7)); 52.89 (N(CH<sub>2</sub>CH<sub>2</sub>)<sub>2</sub>O); 61.96 (ArCH<sub>2</sub>N); 66.78 (N(CH<sub>2</sub>CH<sub>2</sub>)<sub>2</sub>O); 119.87 (C(6)); 122.77 (C(8)); 127.01 (C(5)); 127.93, 128.22 (C(2), C(4)); 129.38 (C(3)); 132.27 (C(9)); 152.77 (C(1)).

**4-Methyl-2-(3-methylbut-2-en-1-yl)-6-(piperidin-1-ylmethyl)phenol (5).** Colorless oil. Yield 0.311 g (91%).  $R_f = 0.62$  (PE/Et<sub>2</sub>O 5:1). Anal. calc. for C<sub>18</sub>H<sub>27</sub>NO (273.42): C 79.07, H 9.95, N 5.12; found: C 79.20, H 9.91, N 5.18. IR (thin layer): 2934, 2857, 2804, 2756, 1476, 1445 (CH<sub>3</sub>, CH<sub>2</sub>); 1611 (C–H); 1248, 1111 (C–O); 860, 785 (=C–H). <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): 1.29 – 1.71 (*m*, 2 H, N(CH<sub>2</sub>CH<sub>2</sub>); 2CH<sub>2</sub>); 1.56 – 1.71 (*m*, 4 H, N(CH<sub>2</sub>CH<sub>2</sub>)<sub>2</sub>CH<sub>2</sub>); 1.74 (*s*, 3 H, C(11)H<sub>3</sub>);

1.75 (s, 3 H, C(10)H<sub>3</sub>); 2.22 (s, 3 H, ArCH<sub>3</sub>); 2.19 – 2.80 (*m*, 4 H, N(CH<sub>2</sub>CH<sub>2</sub>)<sub>2</sub>CH<sub>2</sub>); 3.31 (*d*, 2 H, *J* = 7.1, C(7)H<sub>2</sub>); 3.61 (s, 2 H, ArCH<sub>2</sub>N); 5.36 (*br. t*, 1 H, C(8)H, *J* = 6.9); 6.62 (s, 1 H, C(5)H); 6.84 (s, 1 H, C(3)H); 10.71 (*br.* s, 1 H, OH). <sup>13</sup>C-NMR (75 MHz, CDCI<sub>3</sub>): 17.79 (C(11)); 20.51 (ArCH<sub>3</sub>); 24.05 (N(CH<sub>2</sub>CH<sub>2</sub>)<sub>2</sub>CH<sub>2</sub>); 25.80 (C(10)); 25.82 (N(CH<sub>2</sub>CH<sub>2</sub>)<sub>2</sub>CH<sub>2</sub>); 28.03 (C(7)); 53.85 (N(CH<sub>2</sub>CH<sub>2</sub>)<sub>2</sub>CH<sub>2</sub>); 62.25 (ArCH<sub>2</sub>N); 120.86 (C(6)); 122.96 (C(8)); 126.67 (C(5)); 127.42, 128.02 (C(2), C(4)); 128.86 (C(3)); 132.03 (C(9)); 153.34 (C(1)).

**2-(Azepan-1-ylmethyl)-4-methyl-6-(3-methylbut-2-en-1-yl)phenol (6).** Colorless oil. Yield 0.305 g (85%). *R*<sub>f</sub> = 0.62 (PE/Et<sub>2</sub>O 5:1). Anal. calc. for C<sub>19</sub>H<sub>29</sub>NO (287.45): C 79.39, H 10.17, N 4.87; found: C 79.53, H 10.24, N 4.90. IR (thin layer): 2924, 2857, 2735, 1476, 1447 (CH<sub>3</sub>, CH<sub>2</sub>); 1611 (C–H); 1250, 1144 (C–O); 864, 783 (=C–H). <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): 1.46 – 1.86 (*m*, 8 H, N(CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>)<sub>2</sub>); 1.74 (*s*, 3 H, C(11)H<sub>3</sub>); 1.75 (*s*, 3 H, C(10)H<sub>3</sub>); 2.22 (*s*, 3 H, ArCH<sub>3</sub>); 2.55 – 2.83 (*m*, 4 H, N(CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>)<sub>2</sub>); 3.32 (*d*, 2 H, *J* = 6.9, C(7)H<sub>2</sub>); 3.72 (*s*, 2 H, ArCH<sub>2</sub>N); 5.36 (*br. t*, 1 H, *J* = 6.7, C(8)H); 6.62 (*s*, 1 H, C(5)H); 6.85 (*s*, 1 H, C(3)H); 10.47 (*br. s*, 1 H, OH). <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>): 17.79 (C(11)); 20.53 (ArCH<sub>3</sub>), 25.80 (C(10)); 26.69, 27.71 (N(CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>)<sub>2</sub>); 28.01 (C(7)); 55.17 (N(CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>)<sub>2</sub>); 62.09 (ArCH<sub>2</sub>N); 121.60 (C(6)); 122.97 (C(8)); 126.57 (C(5)); 127.35, 128.14 (C(2), C(4)); 128.92 (C(3)); 131.98 (C(9)); 153.63 (C(1)).

#### Synthesis of compound 7

It was obtained by the described method<sup>[17]</sup> with minor modifications. Calcium chloride (0.5 g, 4.5 mmol) was ground in a mortar with 0.043 g (0.5 mmol) of anhydrous piperazine and 0.035 g (1.2 mmol) of paraform. The powder was transferred to a round bottom flask, then cresol **1** (0.176 g, 1.0 mmol) was added, and the resulting mixture was heated for 35 min at 110 °C. At the end of the reaction, the mixture was cooled to r.t., CHCl<sub>3</sub> (10 mL) was added, CaCl<sub>2</sub> was separated by filtration, washed with CHCl<sub>3</sub> (2 × 7 mL), the solvent was removed under reduced pressure, the final product was precipitated from MeOH.

**6,6'-(Piperazine-1,4-diylbis(methylene))bis(4-methyl-2-(3-methylbut-2-en-1-yl)phenol) (7).** Colorless powder. M.p. 170 – 172 °C. Yield 0.131 g (57%). *R*<sub>f</sub> = 0.33 (PE/Et<sub>2</sub>O 5:1). Anal. calc. for C<sub>30</sub>H<sub>42</sub>N<sub>2</sub>O<sub>2</sub> (462.68): C 77.88, H 9.15, N 6.05; found: C 78.02, H 9.12, N 5.99. IR (KBr): 2953, 2918, 2868, 2818, 1470 (CH<sub>3</sub>, CH<sub>2</sub>); 1254 (C–O); 856, 785 (=C–H). <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): 1.74 (*s*, 6 H, 2×C(11)H<sub>3</sub>); 1.75 (*s*, 6 H, 2×C(10)H<sub>3</sub>); 2.01 – 3.20 (*m*, 8 H, N(CH<sub>2</sub>CH<sub>2</sub>)<sub>2</sub>N); 2.22 (*s*, 6 H, 2×ArCH<sub>3</sub>); 3.31 (*d*, 4 H, *J* = 7.1, 2×C(7)H<sub>2</sub>); 3.68 (*s*, 4 H, 2×ArCH<sub>2</sub>N); 5.34 (*br. t*, 2 H, *J* = 6.7, 2×C(8)H); 6.65 (*s*, 2 H, 2×C(5)H); 6.86 (*s*, 2 H, 2×C(3)H); 10.55 (*br. s*, 2 H, 2×OH). <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>): 17.79 (2×C(11)); 20.49 (2×ArCH<sub>3</sub>); 25.79 (2×C(10)); 28.04 (2×C(7)); 52.31 (N(CH<sub>2</sub>CH<sub>2</sub>)<sub>2</sub>N); 61.35 (2×ArCH<sub>2</sub>N); 120.07 (2×C(6)); 122.79 (2×C(8)); 126.94 (2×C(5)); 127.95, 128.22 (2×C(2), 2×C(4)); 129.36 (2×C(3)); 132.18 (2×C(9)); 152.84 (2×C(1)).

#### Synthesis of compound 8

## Aldehyde 8 was synthesized from cresol 1 by the known method.<sup>[18]</sup>

**2-Hydroxy-5-methyl-3-(3-methylbut-2-en-1-yl)benzaldehyde (8).** Yellow oil. Yield 0.35 g (55%). *R*<sub>f</sub> = 0.77 (PE/Et<sub>2</sub>O 5:1). Anal. calc. for C<sub>13</sub>H<sub>16</sub>O (204.27): C 76.44, H 7.90; found: C, 76.58; H, 7.78. IR (thin layer): 3264, 3142 (OH); 2970, 2918, 2855, 1458 (CH<sub>3</sub>, CH<sub>2</sub>); 1651 (C=O); 1261 (C–O); 1213 (C(CH<sub>3</sub>)<sub>2</sub>); 864, 793 (=C–H). <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): 1.73 (s, 3 H, C(11)H<sub>3</sub>); 1.76 (s, 3 H, C(10)H<sub>3</sub>); 2.31 (s, 3 H, ArCH<sub>3</sub>); 3.34 (*d*, 2 H, *J* = 7.3, C(7)H<sub>2</sub>); 5.30 (*br. t*, 1 H, *J* = 7.7, C(8)H); 7.18 (s, 1 H, C(5)H); 7.20 (s, 1 H, C(3)H); 9.83 (s, 1 H, CH=O); 11.11 (s, 1 H, OH). <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>): 17.77 (C(11)); 20.32 (ArCH<sub>3</sub>); 25.77 (C(10)); 27.29 (C(7)); 119.94 (C(6)); 121.50 (C(8)); 128.66 (C(4)); 130.08 (C(2)); 131.03 (C(5)); 133.34 (C(9)); 137.81 (C(3)); 157.52 (C(1)); 196.65 (CH=O).

## Synthesis of compounds 9 - 11

Molecular sieves (4 Å, 0.4 g) and amine (0.5 mmol) were added to the solution of aldehyde **8** (0.102 g, 0.5 mmol) in anhydrous benzene (3 mL). The reaction mixture was refluxed under an argon atmosphere for 3.5 h. At the end of the reaction, the molecular sieves were separated by filtration, washed with CHCl<sub>3</sub>, the solvents were removed under reduced pressure.

(*E*)-2-((*Cyclopropylimino*)methyl)-4-methyl-6-(3-methylbut-2-en-1-yl)phenol (9). Yellow waxy mass. Yield 0.119 g (98%). *R*<sub>f</sub> = 0.85 (PE/Et<sub>2</sub>O 5:1). Anal. calc. for C<sub>16</sub>H<sub>21</sub>NO (243.35): C 78.97, H 8.70, N 5.76; found: C 80.08, H 10.31, N 4.50. IR (thin layer): 3240 (OH); 3007, 2970, 2916, 2872, 1462 (CH<sub>3</sub>, CH<sub>2</sub>); 1624 (C=N); 1265 (C–O); 864, 792 (=C–H). <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): 0.82 – 1.02 (*m*, 4 H, NCH(CH<sub>2</sub>)<sub>2</sub>); 1.73 (*s*, 3 H, C(11)H<sub>3</sub>); 1.75 (*s*, 3 H, C(10)H<sub>3</sub>); 2.27 (*s*, 3 H, ArCH<sub>3</sub>); 2.89 – 3.00 (*m*, 1 H, NCH(CH<sub>2</sub>)<sub>2</sub>); 3.34 (*d*, 2 H, *J* = 7.1, C(7)H<sub>2</sub>); 5.30 (*br. t*, 1 H, *J* = 6.5, C(8)H); 6.87 (*s*, 1 H, C(5)H); 6.96 (*s*, 1 H, C(3)H); 8.43 (*s*, 1 H, CH=N); 12.83 (*s*, 1 H, OH). <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>): 9.20 (NCH(CH<sub>2</sub>)<sub>2</sub>); 17.78 (C(11)); 20.44 (ArCH<sub>3</sub>); 25.77 (C(10)); 27.81 (C(7)); 40.18 (NCH(CH<sub>2</sub>)<sub>2</sub>); 118.21 (C(6)); 122.44 (C(8)); 127.26 (C(4)); 128.44 (C(5)); 128.93, 132.50 (C(2), C(9)); 132.31 (C(3)); 155.90 (C(1)); 162.14 (CH=N).

(*E*)-2-((*n*-Butylimino)methyl)-4-methyl-6-(3-methylbut-2-en-1-yl)phenol (10). Yellow brown oil. Yield 0.122 g (94%). *R*<sub>f</sub> = 0.85 (PE/Et<sub>2</sub>O 5:1). Anal. calc. for C<sub>17</sub>H<sub>25</sub>NO (259.39): C 78.72, H 9.71, N 5.40; found: C 78.80, H 9.62, N 5.33. IR (thin layer): 3254 (OH); 2959, 2926, 2864, 1464 (CH<sub>3</sub>, CH<sub>2</sub>); 1632 (C=N); 1267 (C–O); 856, 791 (=C–H). <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): 0.95 (*t*, 3 H, *J* = 7.3, NCH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>); 1.32 – 1.50 (*m*, 2 H, NCH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>); 1.58 – 1.77 (*m*, 2 H, NCH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>); 1.74 (*s*, 3 H, C(11)H<sub>3</sub>); 1.76 (*s*, 3 H, C(10)H<sub>3</sub>); 2.27 (*s*, 3 H, ArCH<sub>3</sub>); 3.37 (*d*, 2 H, *J* = 7.2, C(7)H<sub>2</sub>); 3.58 (*t*, 2 H, *J* = 6.8, NCH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>); 5.36 (*br. t*, 1 H, *J* = 7.4, C(8)H); 6.89 (*s*, 1 H, C(5)H); 6.99 (*s*, 1 H, C(3)H); 8.28 (*s*, 1 H, CH=N); 13.71 (*s*, 1 H, OH). <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>): 13.77 (NCH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>); 17.79 (C(11)); 20.29 (NCH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>); 20.44 (ArCH<sub>3</sub>); 25.80 (C(10)); 27.79 (C(7)H<sub>2</sub>); 32.97 (NCH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>); 59.17 (NCH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>); 117.90 (C(6)); 122.44 (C(8)); 126.94 (C(4)); 128.81 (C(5)); 129.19, 132.53 (C(2), C(9)); 132.71 (C(3)); 157.01 (C(1))); 164.61 (CH=N).

(*E*)-4-Methyl-2-(3-methylbut-2-en-1-yl)-6-((octylimino)methyl)phenol (11). Yellow brown oil. Yield 0.154 g (98%). *R*<sub>f</sub> = 0.85 (PE/Et<sub>2</sub>O 5:1). Anal. calc. for C<sub>21</sub>H<sub>33</sub>NO (315.50): C 79.95, H 10.54, N 4.44; found: C 80.08, H 10.31, N 4.50. IR (thin layer): 3455 (OH); 2957, 2926, 2855, 1464 (CH<sub>3</sub>, CH<sub>2</sub>); 1632 (C=N); 1269 (C-O); 855, 793 (=C-H). <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): 0.89 (*t*, 3 H, *J* = 6.3, NCH<sub>2</sub>(CH<sub>2</sub>)<sub>6</sub>CH<sub>3</sub>); 1.17 – 1.47 (*m*, 10 H, N(CH<sub>2</sub>)<sub>2</sub>(CH<sub>2</sub>)<sub>5</sub>CH<sub>3</sub>); 1.58 – 1.79 (*m*, 2 H, NCH<sub>2</sub>CH<sub>2</sub>(CH<sub>2</sub>)<sub>5</sub>CH<sub>3</sub>); 1.74 (*s*, 3H, C(11)H<sub>3</sub>); 1.76 (*s*, 3 H, C(10)H<sub>3</sub>); 2.27 (*s*, 3 H, ArCH<sub>3</sub>); 3.37 (*d*, 2 H, *J* = 7.2, C(7)H<sub>2</sub>); 3.57 (*t*, 2 H, *J* = 6.8, NCH<sub>2</sub>(CH<sub>2</sub>)<sub>6</sub>CH<sub>3</sub>); 5.36 (*br. t*, 1 H, *J* = 7.1, C(8)H); 6.89 (*s*, 1 H, C(5)H); 6.99 (*s*, 1 H, C(3)H); 8.27 (*s*, 1 H, CH=N), 13.73 (*s*, 1 H, OH). <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>): 14.07 (NCH<sub>2</sub>(CH<sub>2</sub>)<sub>6</sub>CH<sub>3</sub>); 17.79 (C(11)H<sub>3</sub>); 20.44 (ArCH<sub>3</sub>); 22.64, 27.78, 29.21, 29.33, 30.91, 31.83 (NCH<sub>2</sub>(CH<sub>2</sub>)<sub>6</sub>CH<sub>3</sub>); 25.80 (C(10)H<sub>3</sub>); 27.19 (C(7)H<sub>2</sub>); 59.54 (NCH<sub>2</sub>(CH<sub>2</sub>)<sub>6</sub>CH<sub>3</sub>); 117.87 (C(6)H); 122.41 (C(8)H); 126.92 (C(4)); 128.80 (C(5)); 129.18, 132.55 (C(2), C(9)); 132.68 (C(3)); 157.01 (C(1))); 164.56 (CH=N).

#### Synthesis of compounds 12 – 14

Sodium borohydride (0.076 g 2.0 mmol) was added to the solution of imine 9 - 11 in anhydrous EtOH (4 mL) while stirring. The reaction mixture was heated under reflux for 30 min. At the end of the reaction, the mixture was cooled to r.t., 3.5 mL of 2 *N* aqueous NaOH solution were added, stirred for 5 min, 10 mL of Et<sub>2</sub>O were added, and stirring was continued for 15 min. Next, the organic layer was washed with 2 *N* aqueous NaCl solution (4×8 mL) to pH 7.0, dried with anhydrous K<sub>2</sub>CO<sub>3</sub>, the solvent was removed under reduced pressure, the product was isolated by column chromatography (PE/Et<sub>2</sub>O with an increase in the fraction of the latter).

**2-((Cyclopropylamino)methyl)-4-methyl-6-(3-methylbut-2-en-1-yl)phenol (12).** Colorless oil. Yield 0.071 g (72%). *R*<sub>f</sub> = 0.47 (PE/Et<sub>2</sub>O 3:1). Anal. calc. for C<sub>16</sub>H<sub>23</sub>NO (245.37): C 78.32, H 9.45, N 5.71; found: C 78.11, H 9.66, N 5.75. IR (thin layer): 3292 (NH, OH); 2965, 2916, 2855, 1477 (CH<sub>3</sub>, CH<sub>2</sub>); 1246 (C–O); 858, 783 (=C–H). <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): 0.45 – 0.60 (*m*, 4 H, NCH(CH<sub>2</sub>)<sub>2</sub>); 1.73 (*s*, 3 H, C(11)H<sub>3</sub>); 1.75 (*s*, 3 H, C(10)H<sub>3</sub>); 2.15 – 2.29 (*m*, 1 H, NCH(CH<sub>2</sub>)<sub>2</sub>); 2.23 (*s*, 3 H, ArCH<sub>3</sub>); 3.29 (*d*, 2 H, *J* = 7.2, C(7)H<sub>2</sub>); 3.99 (*s*, 2 H, ArCH<sub>2</sub>N); 5.33 (*br. t*, 1 H, *J* = 7.3, C(8)H); 6.68 (*s*, 1 H, C(5)H); 6.84 (*s*, 1 H, C(3)H). <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>): 6.04 (NCH(CH<sub>2</sub>)<sub>2</sub>); 17.77 (C(11)); 20.51 (ArCH<sub>3</sub>); 25.78 (C(10)); 28.02 (C(7)); 30.53 (NCH(CH<sub>2</sub>)<sub>2</sub>); 52.81 (ArCH<sub>2</sub>N); 122.32 (C(6)); 122.91 (C(8)); 126.41 (C(5)); 127.74, 128.46 (C(2), C(4)); 129.12 (C(3)); 132.06 (C(9)); 153.15 (C(1)).

**2-((***n***-Butylamino)methyl)-4-methyl-6-(3-methylbut-2-en-1-yl)phenol (13).** Pale yellow oil. Yield 0.087 g (83%). *R*<sub>f</sub> = 0.32 (PE/Et<sub>2</sub>O 3:1). Anal. calc. for C<sub>17</sub>H<sub>27</sub>NO (261.41): C 78.11, H 10.41, N 5.36; found: C 78.19, H 10.37, N 5.30. IR (thin layer): 3316, 3291 (NH, OH); 2959, 2918, 2857, 1470 (CH<sub>3</sub>, CH<sub>2</sub>); 1248 (C–O); 858, 785 (=C–H). <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): 0.93 (*t*, 3 H, *J* = 7.3, NCH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>); 1.25 – 1.46 (*m*, 2 H, NCH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>); 1.47 – 1.61 (*m*, 2 H, NCH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>); 1.74 (*s*, 3 H, C(11)H<sub>3</sub>); 1.76 (*s*, 3 H, C(10)H<sub>3</sub>); 2.23 (*s*, 3 H, ArCH<sub>3</sub>); 2.68 (*t*, 2 H, *J* = 7.0, NCH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>); 3.32 (*d*, 2 H, *J* = 4.9, C(7)H<sub>2</sub>); 3.93 (*s*, 2 H, ArCH<sub>2</sub>N); 5.36 (*br. t*, 1 H, *J* = 6.9, C(8)H); 6.66 (*s*, 1 H, C(5)H); 6.85 (*s*, 1 H, C(3)H). <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>): 13.87 (NCH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>); 17.76 (C(11)); 20.28, 31.72 (NCH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>); 20.51 (ArCH<sub>3</sub>); 25.79 (C(10)); 28.03 (C(7)); 48.50 (NCH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>); 52.87 (ArCH<sub>2</sub>N); 121.94 (C(6)); 122.99 (C(8)); 126.41 (C(5)); 127.47, 128.42 (C(2), C(4)); 128.99 (C(3)); 131.98 (C(9)); 153.59 (C(1)).

**4-Methyl-2-(3-methylbut-2-en-1-yl)-6-((***n***-octylamino)methyl)phenol (14).** Pale beige oil. Yiled 0.108 g (85%). *R*<sub>f</sub> = 0.36 (PE/Et<sub>2</sub>O 5:1). Anal. calc. for C<sub>21</sub>H<sub>35</sub>NO (317.52): C 79.44, H 11.11, N 4.41. IR (thin layer): 3316, 3292 (NH, OH); 2957, 2924, 2855, 1474 (CH<sub>3</sub>, CH<sub>2</sub>); 1250 (C–O); 858, 785 (=C–H). <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): 0.89 (*t*, 3 H, *J* = 6.3, N(CH<sub>2</sub>)<sub>7</sub>CH<sub>3</sub>); 1.18 – 1.40 (*m*, 10 H, N(CH<sub>2</sub>)<sub>2</sub>(CH<sub>2</sub>)<sub>5</sub>CH<sub>3</sub>); 1.47 – 1.61 (*m*, 2 H, NCH<sub>2</sub>CH<sub>2</sub>(CH<sub>2</sub>)<sub>5</sub>CH<sub>3</sub>); 1.74 (*s*, 3 H, C(11)H<sub>3</sub>); 1.75 (*s*, 3 H, C(10)H<sub>3</sub>); 2.22 (*s*, 3 H, ArCH<sub>3</sub>); 2.67 (*t*, 2 H, *J* = 7.0, NCH<sub>2</sub>(CH<sub>2</sub>)<sub>6</sub>CH<sub>3</sub>); 3.32 (*d*, 2 H, *J* = 7.2, C(7)H<sub>2</sub>); 3.93 (*s*, 2 H, ArCH<sub>2</sub>N); 5.35 (*br. t*, 1 H, *J* = 6.8, C(8)H); 6.66 (*s*, 1 H, C(5)H); 6.85 (*s*, 1 H, C(3)H). <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>): 14.06 (N(CH<sub>2</sub>)<sub>7</sub>CH<sub>3</sub>); 17.77 (C(11)); 20.51 (ArCH<sub>3</sub>); 22.62, 28.02, 29.19, 29.39, 29.59, 31.79 (NCH<sub>2</sub>(CH<sub>2</sub>)<sub>6</sub>CH<sub>3</sub>); 25.80 (C(10)); 27.13 (C(7)); 48.82 (NCH<sub>2</sub>(CH<sub>2</sub>)<sub>6</sub>CH<sub>3</sub>); 52.85 (ArCH<sub>2</sub>N); 121.95 (C(6)); 122.98 (C(8)); 126.41 (C(5)); 127.47, 128.42 (C(2), C(4)); 128.98 (C(3)); 132.00 (C(9)); 153.59 (C(1)).

#### DPPH radical scavenging activity

DPPH radical scavenging activity of the compounds was assessed by their ability to interact with DPPH.<sup>[24]</sup> The studied compounds at a concentration of 100  $\mu$ M were added to a DPPH solution in MeOH, stirred, and the solution absorbance was measured at  $\lambda = 517$  nm after 30 min.

#### Fe<sup>2+</sup>-chelation ability

Fe<sup>2+</sup>-chelation ability of the compounds was assessed by the described methods.<sup>[25][26]</sup> A solution of the studied compounds at a concentration of 100  $\mu$ M was added to MeOH, then a FeSO<sub>4</sub> solution was added. The reaction was initiated with a FerroZine<sup>TM</sup> Iron Reagent solution, the mixture was shaken, and the solution absorbance was measured at  $\lambda = 562$  nm after 10 min.

#### Antioxidant activity (brain lipids test)

Antioxidant activity of the compounds was assessed by their ability to inhibit LPO processes in a substrate obtained from the brain of laboratory mice.<sup>[27][28]</sup> After extraction, the brain was homogenized (10%) in a saline solution (pH 7.4) and centrifuged for 10 min. Then the supernatant (S1) containing water, proteins, DNA, RNA, and lipids was collected. The studied compounds in the form of solutions in acetone (final concentration 100 µM) were added to the supernatant. After 30 min, LPO was initiated by adding freshly prepared FeCl<sub>2</sub> and ascorbic acid, the test samples were incubated in a

shaker for 1 h at 37 °C and while slow stirring. The content of thiobarbituric acid reactive substances (TBA-RS) was determined at  $\lambda = 532$  nm; the extinction coefficient  $1.56 \times 10^5$  M<sup>-1</sup> cm<sup>-1</sup> was used for the calculations.<sup>[28-30]</sup>

#### Toxicity, antioxidant activity, and membrane-protective activity (RBCs tests)

Toxicity, antioxidant and membrane-protective activity of compounds were studied in the suspension of RBCs of laboratory mice in phosphatebuffered saline (pH 7.4). The toxicity of the compounds was assessed in an *in vitro* model by their ability to induce RBCs hemolysis. Solutions of the compounds in acetone were added to the RBCs suspension at a final concentration of 10  $\mu$ M and incubated for 5 h at 37 °C. Membrane-protective and antioxidant activities were determined by the degree of inhibition of induced hemolysis, inhibition of accumulation of secondary LPO and oxyhemoglobin oxidation products in RBCs. For this purpose, hemolysis was initiated with a H<sub>2</sub>O<sub>2</sub> solution (0.006%) 30 min after adding solutions of the studied compounds into the RBCs suspension (final concentration of 1  $\mu$ M). The reaction mixture was incubated with slow stirring for 5 h at 37 °C. Every 60 min, an aliquot was taken from the incubation medium, centrifuged for 5 min (1600 *g*), the degree of hemolysis was determined by hemoglobin content in the supernatant at  $\lambda = 524$  nm.<sup>[31]</sup> Hemolysis percentage was calculated relative to the total hemolysis of the sample. The content of TBA-RS was determined using spectrophotometry as described above. Absorption spectrum in the range of  $\lambda = 540 - 640$  nm was analyzed to assess the accumulation of hemoglobin oxidation products. Oxyhemoglobin and methemoglobin content was calculated taking into account the corresponding extinction coefficients.<sup>[32]</sup> Each experiment was conducted in 4 – 10 replicates. Statistical data processing was carried out using Microsoft Office Excel 2007, and 2010 software packages.

## **Supplementary Material**

Supporting information for this article is available on the WWW under https://doi.org/10.1002/cbdv.201xxxxxx.

# Acknowledgement

The reported study was funded by RFBR, according to the research project No. 18-03-00950 a.

# **Author Contribution Statement**

Evgeny V. Buravlev and Irina V. Fedorova: design, synthesis, and structure elucidation; Oksana G. Shevchenko: *in vitro* activity assays; Aleksandr V. Kutchin: concept and project administration. All authors prepared, discussed, and approved the manuscript.

# References

- [1] J. H. P. Tyman, 'Synthetic and natural phenols', Elsevier Science B.V., Amsterdam, The Netherlands, 1994, p. 395 464.
- J. Pedraza-Chaverri, N. Cárdenas-Rodríguez, M. Orozco-Ibarra, J. M. Pérez-Rojas, 'Medicinal properties of mangosteen (*Garcinia mangostana*)', Food. Chem. Toxicol. 2008, 46, 3227 3239.
- [3] H. Hattori, K. Okuda, T. Murase, Y. Shigetsura, K. Narise, G. L. Semenza, H. Nagasawa, 'Isolation, identification, and biological evaluation of HIF-1-modulating compounds from Brazilian green propolis', *Bioorg. Med. Chem.* 2011, 19, 5392 – 5401.
- [4] M. P. Neves, R. T. Lima, K. Choosang, P. Pakkong, M. S. J. Nascimento, M. H. Vasconcelos, M. Pinto, A. M. S. Silva, H. Cidade, 'Synthesis of a natural chalcone and its prenyl analogs – evaluation of tumor cell growth-inhibitory activities, and effects on cell cycle and apoptosis', Chem. Biodivers. 2012, 9, 1133 – 1143.
- [5] Y.-C. Chien, C.-H. Lin, M. Y. Chiang, H.-S. Chang, C.-H. Liao, I.-S. Chen, C.-F. Peng, I.-L. Tsai, 'Secondary metabolites from the root of *Ehretia longiflora* and their biological activities', *Phytochemistry* 2012, 80, 50 57.
- [6] Y. Akihara, E. Ohta, T. Nehira, H. Ômura, S. Ohta, 'New prenylated ortho-dihydroxycoumarines from the fruits of Ficus nipponica', Chem. Biodivers. 2017, 14, e1700196.
- [7] Q. Talhi, A. M. S. Silva, 'Organic synthesis of C-prenylated phenolic compounds', Curr. Org. Chem. 2013, 17, 1067 1102.
- [8] M. Tramontini, L. Angiolini, 'Mannich bases: Chemistry and uses', CRC Press, Boca Raton, USA, 1994.
- [9] G. Roman, 'Mannich bases in medicinal chemistry and drug design', Eur. J. Med. Chem. 2015, 89, 743 816.
- [10] I. A. Dvornikova, E. V. Buravlev, K. Y. Suponitskii, I. Y. Chukicheva, A. V. Kutchin, 'Synthesis of chiral 1,2-diamines from α-pinene and their use in asymmetric nitroaldol reaction', *Russ. J. Org. Chem.* **2015**, *51*, 480 492.
- [11] E. V. Buravlev, I. Y. Chukicheva, O. G. Shevchenko, K. Y. Suponitskii, A. V. Kutchin, 'Synthesis and membrane-protective activity of 4-aminomethyl derivatives of 2,6diisobornylphenol', Russ. Chem. Bull. Int. Ed. 2017, 66, 91 – 98.
- [12] M. D. Reddy, F. R. Fronczek, E. B. Watkins, 'Rh-catalyzed, regioselective, C-H bond functionalization: access to quinoline-branched amines and dimers', Org. Lett. 2016, 18, 5620 – 5623.
- [13] A. Tambo-ong, S. Chopra, B. T. Glaser, K. Matsuyama, T. Tran, P. B. Madrid, 'Mannich reaction derivatives of novobiocin with modulated physiochemical properties and their antibacterial activities', *Bioorg. Med. Chem. Lett.* 2011, 21, 5697 – 5700.

- [14] V.-S. Nguyen, L. Shi, S.-C. Wang, Q.-A. Wang, 'Synthesis of icaritin and β-anhydroicaritin Mannich base derivatives and their cytotoxic activities on three human cancer cell lines', Anti-Cancer Agents Med. Chem. 2017, 17, 137 – 142.
- [15] E. V. Buravlev, O. G. Shevchenko, A. V. Kutchin, 'Synthesis and membrane-protective activity of novel derivatives of α-mangostin at C-4 position', *Bioorg. Med. Chem. Lett.* 2015, 25, 826 829.
- [16] E. V. Buravlev, O. G. Shevchenko, A. A. Anisimov, K. Yu. Suponitsky, 'Novel Mannich bases of α- and γ-mangostins: Synthesis and evaluation of antioxidant and membrane-protective activity', *Eur. J. Med. Chem.* 2018, 152, 10 – 20.
- [17] H. Sharghi, S. Ebrahimpourmoghaddam, 'A convenient and efficient method for the preparation of unique fluorophores of lariat naphtho-aza-crown ethers', *Helv. Chim. Acta* **2008**, *91*, 1363 1373.
- [18] G. Casiraghi, G. Casnati, G. Puglia, G. Sartori, G. Terenghi, 'Selective reactions between phenols and formaldehyde. A novel route to salicylaldehydes', J. Chem. Soc., Perkin Trans. 1 1980, 1862 – 1865.
- [19] J.-J. Helesbeux, O. Duval, D. Guilet, D. Séraphin, D. Rondeau, P. Richomme, 'Regioselectivity in the ene reaction of singlet oxygen with *ortho*-prenylphenol derivatives', *Tetrahedron* 2003, 59, 5091 – 5104.
- [20] Q. Xu, A. A. Kulkarni, A. M. Sajith, D. Hussein, D. Brown, O. F. Guner, M. D. Reddy, E. B. Watkins, B. Lassègue, K. K. Griendling, J. P. Bowen, 'Design, synthesis, and biological evaluation of inhibitors of the NADPH oxidase, Nox4', *Bioorg. Med. Chem.* 2018, 26, 989 – 998.
- [21] R. Venkateshwarlu, B. Chinnababu, U. Ramulu, K. Purushotham Reddy, M. Damoder Reddy, P. Sowjanya, P. Venkateswara Rao, S. Aravind, 'Synthesis and biological evaluation of (-)-kunstleramide and its derivatives', Med. Chem. Commun. 2017, 8, 394 – 404.
- [22] Y. V. Gyrdymova, D. V. Sudarikov, O. G. Shevchenko, S. A. Rubtsova, P. A. Slepukhin, A. V. Kutchin, 'Caryophyllane thiols, vinyl thioethers, di- and bis-sulfides: Antioxidant and membrane protective activities', *Chem. Biodivers.* **2017**, *14*, e1700296.
- [23] A. Danilov, M. Shaposhnikov, O. Shevchenko, N. Zemskaya, A. Zhavoronkov, A. Moskalev, 'Influence of non-steroidal anti-inflammatory drugs on Drosophila melanogaster longevity', Oncotarget 2015, 6, 19428 – 19444.
- [24] K. Sevgi, B. Tepe, C. Sarikurkcu, 'Antioxidant and DNA damage protection potentials of selected phenolic acids', Food Chem. Toxicol. 2015, 77, 12 21.
- [25] U. Sukatta, M. Takenaka, H. Ono, H. Okadome, I. Sotome, K. Nanayama, W. Thanapase, S. Isobe, 'Distribution of major xanthones in the pericarp, aril, and yellow gum of mangosteen (*Garcinia mangostana* Linn.) fruit and their contribution to antioxidative activity', *Biosci. Biotechnol. Biochem.* 2013, 77, 984 – 987.
- [26] J. Lin, Y. Gao, H. Li, L. Zhang, X. Li, 'DNA protective effect of mangosteen xanthones: an *in vitro* study on possible mechanisms', Adv. Pharmaceut. Bull. 2014, 4, 147 153.
- [27] C. I. Acker, R. Brandão, A. R. Rosário, C. W. Nogueira, 'Antioxidant effect of alkynylselenoalcohol compounds on liver and brain of rats *in vitro*', *Environ. Toxicol. Pharmacol.* **2009**, 28, 280 287.
- [28] S. T. Stefanello, A. S. Prestes, T. Ogunmoyole, S. M. Salman, R. S. Schwab, C. R. Brender, L. Dornelles, J. B. T. Rocha, F. A. A. Soares, 'Evaluation of *in vitro* antioxidant effect of new mono and diselenides', *Toxicol. in Vitro* 2013, 27, 1433 – 1439.
- [29] J. A. Buege, S. D. Aust, '[30] Microsomal lipid peroxidation', Methods Enzymol. 1978, 52, 302 310.
- [30] T. Asakawa, S. Matsushita, 'Coloring conditions of thiobarbituric acid test for detecting lipid hydroperoxides', *Lipids* **1980**, *15*, 137 140.
- [31] J. Takebayashi, J. Chen, A. Tai, 'A method for evaluation of antioxidant activity based on inhibition of free radical-induced erythrocyte hemolysis', Advanced protocols in oxidative stress II, Meth. Mol. Biol. 2010, 594, 287 296.
- [32] J. J. M. van den Berg, J. A. F. Op den Kamp, B. H. Lubin, B. Roelofsen, F. A. Kuypers, 'Kinetics and site specificity of hydroperoxide-induced oxidative damage in red blood cells', *Free Radic. Biol. Med.* **1992**, *12*, 487 498.

# Entry for the Graphical Illustration

